

美中生物医药协会会刊

CABA *Connect*

Chinese-American BioMedical Association Official Newsletter

DECEMBER 2009
VOLUME 1, ISSUE 2



🌀 *in this issue* 🌀

- ❖ CABA China Report (P.5)
- ❖ Hua-Chuang-Hui Bioforum (P.12)
- ❖ CABA Medical Devices Symposium (P.18)

Published by Chinese-American BioMedical Association

CABA
P. O. Box 600241
Newtonville, MA 02460

A Message from the Editor

Welcome to the winter 2009 issue of *CABA Connect*, the newsletter of Chinese-American BioMedical Association. We invite you to take a look at this publication for what we have done in the past several months and visit cabaweb.org to learn more about our organization and many upcoming events.

This issue summarizes the major activities organized, co-organized or co-sponsored by CABA from August 2009 to end of the year. Highlights of these events include “2009 New England Chinese Professionals’ Summer Outing on Aug 8th at Hopkinton State Park; “2009 CABA Technology, Investment and Entrepreneurship Symposium” on Nov 14 in Boston; and “2009 CABA Medical Devices and Diagnostics Symposium” on Dec 5 at MIT. The majority of the news reports are from the hands of our dedicated and productive Executive Committee members and coordinators, the exact team who organized and executed these cultural and professional events in a very short period of time. We also included some reports in Chinese previously published by reporters of our media partners.

In this issue, you will also find a selection of news by Chinese media covering CABA’s activities in China. These activities include CABA delegation’s recent visits of several bio-industrial parks and enterprises in Shanghai, Wuxi, Wuhan and Changsha, and CABA’s active involvement as a key organizer or participant of some large international conferences or forums held in mainland China, such as Bio-forum of the 10th Hua-Chuang-Hui (华创会) in Wuhan and World Pharmaceuticals (China) Summit 2009 in Shanghai. The increased publicity of CABA reflects the increased influence and impact of our organization in promoting the collaboration between US and China in biopharmaceutical industries.

The year of 2010 will be another busy year for this young but dynamic organization. Among the many important events under preparations, please mark your calendar for the following two: 1) the New England Chinese Professionals Lunar New Year Gala and the Community Enrichment Forum at Marriot Newton Hotel on February 14 2010, which is co-organized by 11 New England Based Chinese professional organizations aiming to enrich each other, to build bonds within our communities and to celebrate our common cultural and historic heritage; and 2) the 3rd CABA annual conference at MIT Faculty Club on April 10th, 2010. Please check our website for more information.

Wish you and your family all the best in 2010!

Qinglin Che, Ph.D.

Editor, *CABA Connect*

Editor-in-Chief:
Qinglin Che

Editors:
Yongzhong Wang
Tony Yuan

Board of Publications:
Chaoyang Dai, Jun Han,
Yihan Wang, Zhao-Kui Wan,
Junjun Wu, Zhiyong Yang,
Phil Zhang

Contributing Editors:
Zhihong Chen, Zhiyong Yang,
Jingye Zhou

Photographers:
Jun Han and Qinglin Che

CABA CONNECT
Volume 1, Issue 2

Published by:
CABA
P. O. Box 600241
Newtonville, MA 02460 USA
www.cabaweb.org

If you want to subscribe to this
newsletter, please send your
request with updated mailing
address and member
information to
cabaconnect@gmail.com

In This Issue

4. Holiday Greetings from the President
5. *CABA China Report*
美中生物医药协会中国活动速递
8. *New England Chinese Professionals' Summer Outing*
新英格兰华人专业人士夏日野餐会特别报道
10. *China Policy Update*
CABA承办国侨办中国创业政策演讲会
11. *Beijing E-town Promoting Event*
北京市生物医药产业系列洽谈活动
13. *Education and Training*
BioMedical News Round-up
15. *Chuang-Chuang-Hui Report*
Innovation and Collaboration Blossom in China's Pharmaceutical Industry
17. CABA 2009 Technology, Investment & Entrepreneurship Symposium
18. CABA 2009 Medical Devices & Diagnostics Symposium
20. Job Posting
22. Board of Directors & Executive Committee Members Updates
23. 2009 Sponsor list

Cover photo: the Fantastic Skyline of Lujiazui, Shanghai (taken by Qinglin Che)

Disclaimer: *CABA Connect* reserves the right to edit, publish, or reject any submission or its contents. Any articles published by *CABA connect* may not be published elsewhere without CABA's consent and permission. Each article represents the author's opinion, not necessarily that of CABA.

Holiday Greetings from the President

Dear CABA Members and Friends,

First of all, on behalf of the CABA executive committee, I want to thank you for your yearlong support to CABA and wish you and your family a very happy holiday season!

Second, as the president, I would like to take this opportunity to share with you CABA events that took place this year. CABA has been experiencing a rapid and healthy growth in the past two years since its inception in May 2007. It is probably safe to say that CABA has evolved into one of the most active and engaging Chinese professional organizations locally in the Boston Area, nationwide in the US to a greater extent; and overseas in China to a certain degree.

The year of 2009 has been a busy and productive year for CABA. Those who participated and witnessed the many successful events that we have organized and promoted can testify that we have strived to fulfill our mission and achieve our goals. You can easily track our activity reports in this newsletter or at CABA website: [.cabaweb.org](http://cabaweb.org).

While we enjoy reflecting the tremendous accomplishments we have achieved, we attribute all of these to the extraordinary commitment from our Executive Committee members, to the generous support from our sponsors and members, to our collaborators of many professional organizations locally and globally, and of course to our advisors for their constructive suggestions and guidance.

I am confident that the coming year will bring many new opportunities for us to better serve our members and communities. We look forward to an even more prosperous new year in 2010!

Once again, thank you and happy holidays!

Sincerely

Zhao-Kui Wan, Ph.D.
President of CABA



CABA 中国报道**美中生物医药协会中国活动速递**

编者按：在过去的一年里，美中生物医药协会除了立足于北美组织各项科技及文化活动，还多次参与主持、主办及协办在中国召开的国际会议及论坛，并派出代表团走访国内生物医药园区和企业，积极了解中国医药行业发展的最新需求和动态，以更加有效的促进中美之间在生物医药和医疗器械等领域的交流与合作。这里我们汇总了一些来自中国媒体的相关报道，期望您能够从中了解CABA在中国的一些活动。

美中生物医药协会会长到访武汉国家生物产业基地

9月16日，武汉国家生物产业基地建设管理办公室副主任闫忠宁接待美中生物医药协会（CABA）会长万昭奎博士。闫忠宁副主任介绍了生物基地的相关情况，并诚邀美中生物医药协会的专家来武汉发展。万昭奎博士对于武汉的发展及生物城的规划表示赞许，并表示将积极帮助生物基地扩大在海外的影响力、介绍优秀的海外企业及留学生团队来武汉创业。

CABA 主要致力于为在美华人生物医药界人士提供发展的空间和合作的平台。协会的宗旨是推动生物医药专业人士间的交流，特别是与祖国大陆的联系，增进中美两国在生物医药领域的合作。成立以来已成功举办了多次大型活动，得到会员们的积极响应。如成功为无锡惠山举办招商引资推介会，为中国科学院天津研发中心举办招聘座谈会等。2008年CABA联手在美的其他四个华人生物医药协会，成功承办了在湖北武汉举行的第八届华创会国际生物医药论坛。

武汉大学药学院院长胡先明、生物办投资服务中心主任及相关人员参加。（武汉光谷生物城供稿）

2009年全球制药前沿（中国）论坛圆满闭幕

2009年9月18日，为期三天的“2009年全球制药前沿（中国）论坛”正式落下帷幕，此次盛会由上海四杰商务咨询有限公司主办，并得到了美中药协，美中生物医药协会，全国医药技术市场协会CRO联合体鼎力支持。美国强生集团国际科技合作部资深总方监，美中医药开发协会和美中生物医药协会分别主持了17、18号会议。三百余名全球医药界精英从新药创制、产权保护、服务外包、风险投资及现行政策制度等方面全面剖析国际尤其是中国医药界面临的机遇和挑战。

本届高峰论坛以“清晰透视合作机遇，地区竞争，未来展

全球制药前沿（中国）论坛会议现场



望”为主题，并有知识产权研讨会、张江药谷参观、研发外包项目合作洽谈会三大亮点。

随着经济危机影响渐渐消退，医药行业率先进入平稳发展期。跨国药企疯狂并购行为也暂告一段落。重新洗牌后的医药行业将如何再次出现强势增长势头？今后医药产业的格局将会是怎样？

围绕着这些问题与会嘉宾提出了精辟的论断。世卫组织卫生技术评估和管理合作中心主任陈洁教授，上海市食品药品监督管理局研究管理部高惠君主任等从国家政策法规角度指出医疗健康保障是国家工作的重中之重，国家已经在这方面投入大量人力物力，并将继续加大投入力度，并鼓励生物医药企业迅速发展，为人民健康事业进一份力。而强生、默沙东、礼来等跨国药企从自身发展和行业发展趋势表明未来的世界将是生物医药发展的最佳时期，全球优势资源都将集中在这一领域，我们将迎来生物医药爆炸式的增长时期！（生物谷 Bioon.com）

留美华人生物医药代表团访问张江高科技园区和桑迪亚公司

美中生物医药协会代表团访问上海张江高科技园区



10月12日，全美华人生物技术和医药协会联合会 (ALL-CABPA) 代表团对张江高科技园区和桑迪亚医药技术有限公司进行了考察。

代表团一行13人来自活跃于美国的四个最大的留美华人生物医药行业协会组织：美国华人生物医药科技协会 (CBA, 华盛顿)，北美华人生物医药协会 (CABS, 旧金山)，美中生物技术和医药协会 (SABPA, 圣地亚哥及洛杉矶)，及美中生物医药协会 (CABA, 波士顿)。他们此次中国之行是应上海市科委和张江高科技园区邀请。代表团成员们希望此行考察和了解中国生物医药行业的最新发展，寻求潜在的合作机会。

代表团成员从美国波士顿，新泽西，旧金山，和圣地亚哥分别飞抵上海。12日上午访问考察了桑迪亚公司。在为期半天的访问中，他们受到了桑迪亚公司董事长兼总经理王晓川博士的热情接待。王晓川博士向代表们介绍了中国CRO行业以及桑迪亚公司的发展现状。她还特别提到：桑迪亚公司欢迎更多优秀的生物医药行业专家和中高级管理人员来华加盟，一起把桑迪亚做得更好。代表团还参观了桑迪亚实验室和研究设施，并与部分研究人员交流了在中国和美国从事生物医药研究的体会。

下午，张江生物医药基地总经理王兰忠先生接待了代表团。始建于1994年的张江生物医药基地，被誉为张江“药谷”，是整个上海乃至全国生物医药研发产业的龙头。王兰忠先生对客人们详细介绍了基地的发展历程和现状，还介绍了张江对于海外人才和投资的优惠政策。之后，代表团参观了张江高科技园区的展览大厅，对张江的投资和人才引进，以及如何张江创业等各方面的政策有了一个更为清晰的了解。


访问结束后，客人们纷纷表示，张江园区和桑迪亚的发展给他们留下了深刻印象，他们看到了中国政府为促进中国生物医药行业所付出努力的结果，相信张江的明天一定会更加美好。大家真诚希望今后能够有机会进行合作。

(上海美通社亚洲 供稿)

美中生物医药协会博士团考察官林

10月14日，美中生物医药博士团一行来到宜兴市官林镇，实地考察该镇生物科技园投资创业环境。

美中生物医药协会代表团访问官林生物科技园及盛福药业有限公司



官林镇在做大做强电线电缆产业的同时，始终致力于寻找新的经济增长点，集聚发展后劲。特别是今年，该镇明确了大力发展生物科技产业的工作目标，加速推进生物科技园基础设施建设和相关招商工作。据悉，美中生物医药协会是美国波士顿地区生物医药界华人科学家和企业家的一个重要团体。当天，博士团一行就产业优惠政策、双方合作模式及园区配套设施建设等问题展开了交流。他们表示，争取能早日把生物医药行业的高新技术成果嫁接到官林来。(宜兴日报)

第九届“华创会”圆满落幕 生物医药板块成热点

10月16-17日，2009华侨华人创业发展洽谈会在武汉国际会展中心举行。本届“华创会”由国务院侨务办公室、湖北省人民政府暨武汉市人民政府共同主办，湖北省侨办、湖北省科技厅、武汉市侨办、武汉东湖新技术开发区管委会承办。本届华创会参会代表2000多人，来自海外的代表约900人，是历次规模最大的一届。

10月17日上午，2009华创会武汉远大国际生物医药论坛在武汉国际会展中心东湖厅举行，武汉国家生物产业基地建设管理办公室是本次国际生物医药论坛承办方之一。湖北省人民政府副省长赵斌、国家食品药品监督管理局药品注册司司长张伟莅临会场并致辞。来自海外及国内的生物医药界人士约400人参加了论坛。

武汉远大国际生物医药高峰论坛会议现场



论坛演讲由美中生物医药协会（CABA）王义汉博士主持，来自美国、加拿大等国家10名优秀海外生物医药行业代表发表了精彩的演讲，共论生物医药产业发展，为湖北特别是光谷生物城发展生物医药产业献计献策。

海外华人华侨加深与国内生物医药领域交流合作：全美六大协会聚会光谷生物城

10月17日下午，来武汉参加2009华创会国际生物医药论坛的全美六大华人生物医药协会的部分代表30余人实地考察了武汉国家生物产业创新基地和产业基地生物医药园、生物农业园、医疗器械园。活动后与会代表还参加了湖北省、武汉市食品药品监督管理局、武汉东湖高新区管委会和武汉国家生物产业基地建设管理办公室联合主办的2009华创会国际生物医药论坛招待晚宴。省食品药品监督管理局局长邹贤启，东湖高新区党工委书记、管委会主任刘传铁等领导出席活动并会见了这六大华人生物医药协会的海外代表。

六大华人生物医药协会分别是王义汉、吴俊军博士等代表的美中生物医药协会（CABA）；杨大俊、赖寿鹏博士等代表的美国华人生物医药科技协会（CBA）；夏明德博士

华创会国际生物医药论坛部分代表参观光谷生物城



等代表的美中医药开发协会（SAPA）；李乐平、苗世昌博士等代表的北美华人生物医药协会（CABS）；蔡辉博士等代表的美中生物技术与制药协会（SABPA）；王建新博士等代表的北核协会（Bayhelix）。

省食品药品监督管理局副局长黄华恩、傅铁成，局纪检组长、党组成员熊琴芝，副巡视员梅旭辉，市食品药品监督管理局局长李燕，东湖高新区管委会副主任宋治平，武汉国家生物产业基地建设管理办公室副主任闫忠宁参加。

湖北省食品药品监督管理局与美中生物医药协会、美国华人生物医药科技协会、美中生物技术与制药协会、北美华人生物医药协会、美中医药开发协会、北核协会等6个美国华人医药协会分别签订合作意向书，双方计划协作建立湖北医药企业档案库、海外华侨华人生物医药专业库，并将在人才培养方面开展深入合作。（新华网）

美中生物医药协会专家来湘访问

应省政府郭开朗副省长邀请，美中生物医药协会前会长吴俊军博士一行来湘访问。

在湘期间，吴俊军博士一行参加了2009中国（长沙）科技成果转化交易会，到长沙市国家生物产业基地进行考察，并就生物医药科技产业合作在长沙市召开专门座谈会。省政府科技顾问曾庆炎主持会议，省科技厅罗亚军副厅长，社会发展科技处负责人出席会议。参加座谈会的还有长沙市科技局、长沙市国家生物产业基地管委会负责人，湖南省基因工程药物中试基地、中南大学药学院专家，湖南九典制药有限公司、湖南纳新生物产业投资基金有限公司等9家制药公司和投资公司负责人（湖南日报）

新英格兰华人专业人士夏日野餐会特别报道

四专业团体五百余青中老少夏日同聚共享郊游乐

星岛日报记者 周菊子

跨向新世局，潮流兴团结。纽英伦地区四个专业人士团体首次携手举办夏日郊游活动，在八月八日这天吸引来四、五百人聚集到霍普京顿(Hopkinton)州立公园，享受了一整日的蓝天、白云、绿草与清新空气。

北美中华医学会(American Chinese Medical Association (ACMA))、美中生物医药协会(Chinese American BioMedical Association (CABA))、中美知识产权协会(Chinese American Intellectual Property Association (CAIPLA))和海外华人企业家联合会(and Overseas Chinese Entrepreneurs Association (OCEAN))是在今年一月三十一日时首次合作，以纽英伦华人专业人士联合会的名义，办过一场大型春节联欢晚会。八日这天则是四会首次携手办夏日郊游活动。前述四会各派两人为代表，统筹办理了八日的夏日郊游活动。

来自各个组织、住在不同市镇的专业人士，这天不但携家带着，在霍普京顿州立公园搭起帐篷，摆出折椅，三三两两的围聚聊天，享用金门超市总经理暨海外华人企业家联合会会长胡运焯等人赞助的中式美食，还免费享受心脏、肠、胃、脑等十几种不同专科医师的义诊，以及律师咨询。

统筹这次郊游活动的 OCEAN 教育中心副主任周梅，CABA 副会长戴朝阳表示，这是他们为了令联合会活动更多元化，给出席者在开心玩玩之外，更多的参加活动理由，也给各专业人士展现其专业技能，打知名度机会，跨领域交流，可一石数鸟的有心安排。

当天他们不但有注册组的车庆林等人，一早七、八点就先赶到公园，抢占靠进游泳池、排球场，有大批桌椅可供人休憩的地点，烧烤小组的邝萍萍，活动组的杨钦钊

等人也都各司其职，和同组义工忙得不可开交。其中四名年轻女生自成一组，为小朋友举办有奖游戏摊的活动，更为这一活动添加了培训青少年提计划、办活动能力的特色。

周梅及戴朝阳表示，四会各派出二名代表筹办这一个大活动。但当天到会的四、五百人得以在暖阳普照下，欢笑声不断中愉快渡过一天，得归功于所有义工们的热心服务。

当天出席人数最多的团体是美中生物医药协会。该会现任会长万昭奎表示，大纽英伦地区有许多华人及华人专业团体，平日各自活动，甚少联系。近年的中国崛起大环境，促使热心人士兴起把分散的华人聚集起来这念头。四会的主要干部共廿多人，于是组成联合委员会，开始推动、筹办这一年至少两次的跨会联合活动，希望能打破专业领域藩篱，既扩大会员们的交流范围，也为各专业人士拓宽宣传生意、促进商务的机会。



拔河是当天活动的最高潮。(菊子摄)

纽英伦中华资讯网路协会会长陆德礼，曾任麻省理工学院华人科技会会长的麻省理工学院教授朱正亚，Ascend

这金融协会，以及多个学生学者联合会的代表，八日也都共襄盛举的应邀到会。



张引(后右一起)、王义汉、陆德礼、万昭奎、顾鸿生、朱正伦、OCEAN 副会长赵进、周梅(前右二)、车庆林(前左一)等人是华人专业人士联合会夏日郊游活动的主要筹办人。(菊子摄)

八日出席活动的创办中美知识产权协会的张引，现任会长顾鸿生；创办北美中华医学会的朱正伦；共同创办并曾任中美生物医药协会会长王义汉及韩军，以及现任

会长万昭奎，海外华人企业家联合会教育部主任吴凯彬等人也都表示，为会员创造机会，为社区提供服务，是他们共同的理想，各会今后除仍将各自为所属会员筹办属于自己会内的活动，也将现有的成功基础上，至少一年两次的举办这样的联合大会。



四、五百人一起午餐，场面盛大。(菊子摄)

中国创业政策演讲会后记

制造王国走向质变，“中国创造”大幕拉开

侨报周刊记者李琳 报道

经过二十多年“中国制造”的量变积累、数亿人民呕心沥血的辛勤劳作，中国开始走上科技创新、自主研发的新发展轨道，除了空前规模的巨额资金投入，吸纳人才、尤其是海外高学历创新型人才，已成为目前国家宏观政策的重头戏之一。

10月29日至11月11日，中国国务院侨务办公室组派“中国创业政策咨询报告团”一行四人访问美东五城——华盛顿、北卡罗利市、亚特兰大、波士顿、和纽约，介绍国家宏观经济、科技形势，建设创新型国家与华人华侨发展机遇，回国发展的优惠政策以及具体操作等，并提供现场咨询，受到有志回国发展创业人士的欢迎和好评。

报告团成员来自中国科技部国际合作司、国家发展和改革委员会（发改委）宏观经济研究院、和国务院侨办，由侨办经济科技司巡视员兼副司长张健青带队，其他成员包括中国科技部国际合作司参赞王启明、发改委宏观经济研究院科研管理部副主任史育龙、侨办经济科技司处长于建明。

11月7日，报告团来到高校云集的波士顿，在哈佛大学燕京报告厅举办“中国创业政策演讲会”，吸引了逾200位学生学者、专业人士与会。波士顿报告会由中美生物医药协会（CABA）、亚洲文化中心主办，由哈佛中国学生学者联合会主持，留美华人企业家协会

(OCEAN) 等三十多家华人社团协办，CABA 副会长戴朝阳任大会主持人。



CABA 副会长戴朝阳主持会议

在“宏观战略、科技兴国、危机契机、创业中国”的大背景下，王启明和史育龙分别就《中国科学技术的重大转变和产业发展机遇》、《金融危机以来中国经济的“变”与“不变”》为题发表主题演讲。

王启明表示，中国正在经历发展模式的巨大战略转型，科技产业将取代劳动密集型产业成为经济发展的动力和基础，这为科技人才、海外归国人才提供了良好的发展契机。国家将“自主创新、重点跨越、支撑发展、引领未来”定为 2020 年之前的科技发展方针，2008 年对科研的投入位列世界前茅，并取得了“ARJ21”自主研发飞机试飞成功、“神七”太空行走、世界最快速铁路京津线通车、量子密码通讯、超导研究等一系列重大科研项目的成功。但同时，中国的原始创新能力尚不够，还处在用外国的技术做科学的阶段，因此，国务院决定投入 1000 亿元支持科技创新，主打“中国创造”牌。

目前参与科技建设的海外归国人员存在“三多三少”的问题，即人数多，领军人才少；高校研究者多，开发创业者少；选择沿海地区者多，到内陆地区者少。王启明希望这种状况能够得到改善。

史育龙介绍了中国经济的总体特征：增长快、体量大、影响力显著提高、推动社会迅速变革。他表示，席卷世界的金融危机也不可避免地带给中国冲击，尤其是出口领域。危机改变了中国经济增长的外部环境，但没有带走中国发展的重要战略机遇期；改变了中国经济持续快速增长的曲线，但没有改变中国发展的基本面和总体态

势，经济复苏的基础已建立；危机正改变固有的增长方式，但长期积累形成的内在矛盾没有改变，以能源为代表的“绿色复苏”成为新的热点；危机改变了中国在全球经济格局中的地位，使其更受重视，但中国仍是一个发展中国家。



张健青(前排左2)王启明(后排左2)史育龙(后排左3)与部分会议组织者

最后，报告团呼吁海外留学生、华人、华侨不要错过这次大显身手的机会，积极通过各种方式参与到这场意义深远的重大转变中，在振兴中华的伟大事业中找到自身的价值，实现与祖国共强盛的夙愿。



哈佛燕京图书馆的会议现场

Boston-Beijing**记北京市生物医药产业系列洽谈活动**

侨报周刊记者李琳 报道

9月，CABA 承办“投资北京”信息会

也许从现在开始，“投资”这个中文词汇将会有新的阐释，从理所当然的“资金资本投资”过渡到求贤若渴的“人力人才投资”。当业已高度发展、全面现代化的祖国首都北京也大声发出“归来吧”的呼唤，海外学人从没有像今天这样强烈地感到自己的头脑、自己的学识是如此重要且价值不菲的资本。



“投资北京”信息会现场

9月19日，“投资北京”代表团在北京市投资促进局副局长周卫民的带领下，与美中生物医药协会（CABA）联合在麻省理工学院教工俱乐部举办信息发布会。北京方面派来了市科学技术委员会人事教育处处长曾立坚、北京海外学人中心人才开发部业务主管娜琳、中关村管委会人才处处长杨彦茹、北京经济技术开发区人事局局长赵莉、北京经济技术开发区汇龙森国际企业孵化有限公司总经理朱强，阵容可谓十分强大。

代表团这次走访纽约、波士顿、华盛顿等几个美东中心城市，带来了北京市引进科技、工业人才的各项最新政策。周卫民介绍了目前北京市对于科技创新领域的政策支持和发展目标，包括新出台的《北京市高新技术成果转化项目认定办法》、《自主创新产品认定办法》、以及正在试行的《关于加快科技企业孵化器发展若干规定》，表示北京

在目前取得的经济建设成就的基础上加大了引进人才的力度，走科技创新之路。

曾立坚对记者表示，国家特别重视海外人才的引进和科技企业的孵化，并专门拨出巨额资金。目前已有多家省、市、院校据此抢先制订了“百人计划”、“千人计划”，率先组团到海外招才（譬如本报上周报道的中科院北美招才活动），预计其他各级单位将跟进，参与到“抢人才”的大潮中去。

娜琳介绍了《北京市鼓励海外高层次人才来京创业和工作暂行办法》以及《北京市促进留学人员来京创业和工作暂行办法》，强调了“尊重人才、特事特办”的原则。

杨彦茹为中外知名的中关村科技园总结了“一二三四五”个特点。“一”是国家唯一的自主创新示范区；“二”是持续引导新兴产业和吸引现金人才两大重点；“三”是人才+钱财、企业家的培养、科教资源丰富三大优势；“四”是海外联络处、代办工商注册等四个工作体系；“五”是提供上市融资、申请重大产业化项目等五项服务。

赵莉向来宾介绍了大家还不太熟悉的位于昔日皇家猎场亦庄的北京经济技术开发区，强调要把亦庄建设成为繁荣、和谐、宜居的新城，来支撑科技工作人员的生产生活。她充满热情地表示，这次来美让她看到中美之间的不足，愿意学习美国先进的科技创新理念和机制，但自信中国人才才是最宝贵的资源。

朱强用平实幽默的语言介绍了汇龙森作为一家民营创业孵化企业，提供的“保姆式服务”和高层次沟通，希望有志回国创业者能够充分利用国家和各级政府的支持，勇敢走出第一步，汇龙森会提供专业的服务，让加盟者梦想成真。

而成立不到两年的CABA能够成功举办如此高规格的大型活动也颇为引人注目。会长吴俊军表示，CABA在成立之初便与北京方面建立脉络联系，这次“投资北京”代表团首访波士顿，也找到CABA联合举办，此外，为了扩大活动的影响，CABA还联合了本地8家专业人士协会协办本次活动。副会长戴朝阳表示，由于场地有限，只能容纳200多人，所以协会一开始没有在媒体上发布消息，果然

不久内部注册的人数就已超过预期，可见这次活动的受欢迎程度。



北京代表团与CABA会议组织者合影

11月，北京亦庄生物医药代表团再访波城

波城专业人士、学生学者或许还对9月末一场“投资北京”的大型信息活动记忆犹新，今番北京方面趁热打铁，再次由北京市投资促进局周卫民副局长领队，带领13位来自政府投资部门和生物医药产业的代表，在美中生物医药协会（CABA）的安排下，于11月28日感恩节周末在麻省理工举办“北京市生物医药产业洽谈会”，重点推介有“药谷”之称的北京亦庄。

会议议程紧凑，并为参会者提供了有关北京方面的各种中英文资料，是一个十分难得的了解北京、并与政府官员、企业人士面对面交流的机会。CABA理事车庆林表示，虽然时值长周末，但信息发布后，仍有120人注册报名，而实际到场人数则远远超过预期。

活动美方联络人、CABA前会长吴俊军做开场致辞，介绍了与会嘉宾。周卫民之外，代表团有北京经济技术开发区管委会巡视员杜新安、北京投资促进局产业促进处处长张新民、北京经济技术开发区科技局局长李群虹、北京经济技术开发区产业促进局局长姜玫、北京市投资促进局产业促进处副主任科员郭晋杰、北京经济技术开发区管委会法制办公室副主任科员杨晓、北京经济技术投资开发总公司招商部副经理王晓波、北京泰德制药有限公司副总经理王月明和安峥、舒泰神（北京）生物制药股份有限公司副总经理蒋立新、百泰生物药业有限公司董事长白先宏、北京奥特康森药物科技服务有限公司副总经理张二利。



活动美方联络人、CABA前会长吴俊军做开场致辞

在CABA理事会理事王义汉、车庆林主持下，演讲嘉宾一一与参会者见面，并发表主题发言。周卫民介绍了目前北京市对于科技创新领域的政策支持和发展目标，指出拥有年百分之二十二经济增长率的首都对海外投资企业提供多项优惠，并且也乐于投资海外业绩良好的创业公司。杜新安和王晓波向来宾介绍了位于昔日皇家猎场亦庄的北京经济技术开发区，重点宣传了有中国“药谷”之称的亦庄在生物医药产业方面的政策、投资、发展现状和前景。作为北京市新发展的开发区，亦庄在基础设施建设方面有后发优势，设施完善、观念超前，并且与市区相距不远。医药产业目前是中国发展最快的行业之一，而亦庄凭借地理、人才、政策优势，要建设成为新药孵化基地。白先宏、王月明、张二利先后以自身创业为例，介绍了亦庄在其企业成长过程中扮演的至关重要的角色和所提供的帮助。

吴俊军及王义汉会后表示，近期生物制药业的迅速发展使得信息分享成为CABA的核心工作，12月5日将在麻省理工教工俱乐部主办2009医疗器械和诊断技术研讨会。



会议组织人员及部分代表合影

Special Reports

CABA Education Center & Regulatory Affairs Training Program

Reported by Shiwen Lin, Ph.D., and Wendy Zhang, Ph.D. Co-directors of CABA Education Center



CABA Education Center, led by Drs. Shiwen Lin and Wendy Zhang, is an entity within Chinese American BioMedical Association (CABA). CABA Education Center is dedicated to identify and meet the needs of pharmaceutical and biomedical professionals in the current globalized industry to better understand US FDA regulations, to advance career development, and to achieve corporate or government compliance goals. These goals are being achieved by providing high-quality training and continuing education to industry professionals, including professionals and government agencies from China.

Two training programs were successfully executed. The former was held at Harvard Medical School from June to July 2009. It attracted more than 30 eager attendees from local pharmaceutical industry and academic institutions. The latter was offered to 4 visiting professionals from the Wuhan SFDA in Lexington, MA, from August 10, to November 1, 2009. This program was designed to focus on regulatory affairs in biotechnology, pharmaceuticals, medical device as well as clinical project management, drug development perspectives, commercialization, and post-marketing management. Training were offered in a variety of formats including seminars, lectures, discussion, visits to local bio/pharma companies (Pfizer, Novartis, Genzyme, Ariad, etc.), FDA, local professional organizations including Mass Biotech Council (MBC), universities, and hospitals including Beth Israel Deconess Hospital.

CABA Education Center made respectful commitment to these training programs as highlighted in the latter 3-month Regulatory Training

program for the trainees from Wuhan SFDA. The organizers were deeply involved the whole training process starting from inviting the trainees to come to the US, training in English language, arranging logistics, designing training topics for the regulatory affairs, inviting and interviewing teachers for the training topics, coordinating the training classes, arranging site-visits, helping the trainee presentations at forums and graduation ceremony. The following is a selected list of topics included in the training program:

Regulatory Affairs in US Bio/Pharma Industry and International Regulations, Basic cGMP & Case Studies.

1. Drug Safety and Reporting, Off-label Use - Regulations from a Clinician's Perspective.
2. Intellectual Property in the Bio/Pharma Industry
3. Heparin Contamination Case, Regulations in Biologics.
4. Global OTC Drugs Clinical Trials Design, Submission Dossier for Registration and Post-marketing Clinical Study.
5. Introduction of Drug Discovery
6. Clinical Trial Design, Filing and Management.
7. 1). FDA Updates (general information on various offices, inspections). 2). Drug Product Development Process and GMP Practice in

- Pharma/Biotech Industry, 3). FDA Inspections and 483s.
8. Overview of ISO 10993 Standards - Biological Evaluation of Medical Devices.
 9. Establishing Efficient Quality Systems to Ensure Drug Safety and Compliance: Strategies for Pharmaceutical and Biotech Companies.
 10. FDA regulatory of Medical Device Quality Systems and Post Market Surveillance.
 11. FDA Regulation Medical Device.
 12. Overview of Bio/pharma Industry Development in USA.
 13. Food Regulation and Drug Regulation: Resemblances and Difference.
 14. Setting Up Efficient and Compliant Quality and Monitoring Systems: Independent and Third-Party Roles and Responsibilities.
 15. Good Manufacturing Practices: What Counts and What Happens When Inspections Go Wrong.
 16. The FDA's Fundamental Functions: Creating and Enforcing New Regulatory Standards.
 17. Quality Systems and Compliance Development for Human Somatic Cell Therapy Products: Lessons Learned from 19 Years of Experience.
 18. The FDA Field Office: Roles, Responsibilities, and Agents for Change.

During the training program, CABA Education Center organized a promotional forum at MIT on October 17, 2009, for the 4 trainees to showcase the Wuhan SFDA agency and the Biolake - one of the 10 national Chinese Biotech industry parks. The forum was attended by and well received by more than a 100 professionals from MA, CT, RI, and NY.

At the end of the training program, the 4 trainees had a chance to visit the MBC, and the visitors' gaining of expertise and professionalism gave the host an outstanding impression. Activities of the training program received very positive media coverage from World Journal, Boston News Reports, and Reuters.



raduation ceremony of the training program was organized on October 31, 2009, at Harvard Medical School. A keynote speech by VP of Novartis, Steve Projan, Ph.D., the presentations by the 4 trainees, and the certificate awarding to the trainees by the teachers were the highlights of the memorable graduation event witnessed by many attendees from CABA, Harvard Medical School and a visiting delegation group from the Wuhan Biolake management.

Success of the first Regulatory Affairs training program offered to Chinese visitors were attributed to a group effort from many CABA leaders including Yihan Wang, Ph.D, Zhao-Kui Wan, Ph.D., Zhihong Chen, Ph.D., Zhengdong Zhu, Ph.D., Junjun Wu, Ph.D., Sue Ma, MD., Jia Huang, Ph.D. and many Executive Committee members and coordinators. Riding on the success from this year's training programs, CABA will continue to dedicate efforts to fulfill the growing needs in similar training program for visitors from the Chinese pharmaceutical and biomedical industry in the future.

Hua-Chuang-Hui Bio-Forum Report

China's Biomedical Industry: innovation and collaboration blossom

Reported by Qinglin Che, Ph.D.

On Oct 17, 2009, more than 400 professionals, scientists and executives from biopharmaceutical industries, research institutes and universities, including over 150 overseas guests, gathered at East Lake Hall, Wuhan Exhibition and Convention Center of Wuhan, Hubei to attend the Grand-Pharma International Bio Forum organized by Hubei Provincial FDA and Wuhan City government. This forum is one of the many activities of 2009 Hua-Chang-Hui conference, a three-day event organized by Overseas Chinese Affairs Office of the State Council and the government of Hubei Province, which attracted more than 800 guests from China and abroad.



Mr. Xian-Qi Zou, Director of Hubei Provincial FDA, hosted the opening ceremony. Mr. Bin Zhao, Vice governor of Hubei Province, delivered the opening remarks. He emphasized, in order to accelerate the growth of local biopharmaceutical industry, the provincial government is taking significant steps to attract more outstanding overseas talents and global investments. Via collaboration with overseas professional organizations, a high level global talent pool composed of seasoned experts will be established to provide broad and in-depth supports to the local enterprises for a healthier and more sustainable growth. Mr. Guofan Xie, President and CEO of Wuhan Grand-Pharmaceutical Group gave a welcoming address representing the domestic pharmaceuticals companies in China. He stressed the importance and

urgent demand for advanced technology, novel products and senior executive teams from the local companies, and he welcomed all kinds of collaborations with overseas enterprises and entrepreneurs.

Dr. Yihan Wang, Associate director of Medicinal Chemistry at Ariad Pharmaceuticals, Co-founder of Chinese American BioMedical Association, hosted the forum program. In his opening remarks, Dr. Wang reviewed the evolution of this forum as one of the multiple outcomes of long term collaborations between overseas Chinese professional communities with local governments and high-tech parks. As the co-Chair of this forum's plenary committee, Dr. Wang expressed his appreciation to those who had been working so hard to make this forum possible and to get it in such a good shape.

Dr. Zhihong Chen from Eisai Research Institute and Dr. Qinglin Che from Synta Pharmaceuticals, both executive committee members of CABA, co-hosted the two sections of the forum.

The first section of the forum was kicked off by Dr. Junjun Wu (principle scientist at Pfizer; immediate past President of CABA), who reviewed the current hurdles and challenges in global drug discoveries and shared his opinions on how to accelerate

the growth of China's bio/pharma industry during the global economic downturn. Afterwards, Dr Dajun Yang (President of Ascenta Shanghai), Dr. Mingde Xia (Senior director of Johnson & Johnson; former president of SAPA), Dr. Shoupeng Lai (Consultant at AnGes; General Secretary of CBA) and Dr Xiaorong Sun (President and CEO at Wuhan Landing Medicals Hi-Tech Ltd) respectively gave their wonderful presentations covering a wide range of topics such as US-China collaboration, emerging technology in biopharmaceuticals industries and medical devices for early diagnosis of cancer *etc.*

The second section of the forum was featured by several recent returnees and senior entrepreneurs. Dr. Shangjin Yang, the Chief Scientist at Wuhan Grand-Pharmaceutical Group (WGP), updated the current progress of anticancer drugs at WGP. Dr. Yuanchun Ma, President and CEO of Canadian Phytopharmaceuticals, Richmond, British Columbia, Canada, introduced the technology used in the quality controls of formulated botanical products. Dr. Xiangming Fang, Sr. VP and CSO of EBioCenter and President of SABPA-San Diego, showcased the active roles played by overseas Chinese Professional Organizations like SABPA in bridging China and US in technology, innovation and entrepreneurship. Dr. Dan Zhang, CEO of Fountain Medical Development, Tianjin, China, overviewed prospects of the preclinical and clinical CRO industry in China. And finally, Dr. Hua Tu, CEO at Lakepharma, Belmont, CA, shared with the audience his personal story to build up Lakepharma, a biotech company specializing in advancing DNA and protein engineering technology.



This half-day forum was highly successful - The audience was amazed by the high quality of presentations, the fabulous logistics and the exceptional networking opportunities with both local and international experts.

After a lunch reception at Wuhan Shangri-La Hotel, in the afternoon, the overseas delegation visited the Guanggu Bio-Lake Development Zone accompanied by Mr. Zhongning Yan, Associate Director of Wuhan National Bio-Industry Base. The delegation was highly impressed by the new drug screening service platforms and the bio-enterprises incubators. Some guests indicated their interests in building enterprises in the industrial park. Following the visit, the delegation attended a banquet reception hosted by Hubei Provincial FDA and Bio-Lake.



The success of this forum was not only measured by its size and scope of participation and long term effects but also by its immediate results. In terms of economic outcome, contracts with total value of 470 MM RMB were signed during the forum between participating enterprises and business parks.

For many overseas participants, Hua-Chuang-Hui is not the only stop of their China trips. Attending conferences, visiting the industrial parks, negotiating with potential partners, giving speeches in universities, are typical items in their calendars. Everyone believes, innovation and collaboration are going to blossom in China's biomedical industry in the very near future.

CABA Special Symposium 1

2009 Technology, Investment and Entrepreneurship Symposium

Reported By Phil Zhang, Ph.D., J.D.; Zhiyong Yang, Ph.D.

CABA 2009 Technology, Investment and Entrepreneurship Symposium was held on November 14, 2009 at Boston DoubleTree Hotel on the Charles River. The theme of the 2009 Symposium was “Entrepreneurship in Life Sciences.” The annual Symposium continued its tradition and provided a unique and valuable forum where entrepreneurs, scientists, engineers, business executives, academic researchers and administrators, financial, legal and investment professionals, and government policy makers engage in an in-depth discussion and exchange on various topics that impact entrepreneurship in the life science industries. Experts in biotechnology, finance, tax and law shared their perspectives and experience and provided helpful guidance on how biotech entrepreneurs may better navigate the turbulent waters of today’s world.

Speakers at this year’s Symposium include Kevin Counihan, Chief Marketing Officer of the Commonwealth of Massachusetts Health Connector Authority; well-known Chinese-American entrepreneur Dr. Roger Tung, founder and CEO of Concert Pharmaceuticals; investor and deal maker Mark Tang, CEO of World Tech Ventures LLC; Christa Bleyleben, founder of MassGlobal Partners LLC and former head of Massachusetts Office of International Trade; Dr. Konstantin Linnik, Senior Patent Counsel at Pfizer; Linda Ji, Senior Counsel at Foley & Lardner LLP; Pauline W.F. Mak, partner and accountant at global accounting firm KPMG; and Dr. Jean Qiu, founder of Nexcelom Bioscience.



The 2009 Symposium was hosted by CABA and co-sponsored by a number of sister professional associations in the greater Boston region, including Chinese-American IP Law Association (CAIPLA), American-Chinese Medical Association (ACMA), Overseas Chinese Entrepreneurs Association (OCEAN), New England Chinese Information & Network Association (NECINA), Mount Jade New England (MJNE), and Association of Pan-Asian Leaders in Finance and Accounting New England (ASCEND-NE). The organizing team includes Drs. Jimbo Lee, Philip Zhang, Roger Xie, Zhiyong Yang, Yihan Wang, Zhao-Kun Wan, Qinlin Che, and others.



CABA Special Symposium 2

2009 Medical Devices & Diagnostics Symposium

Reported By Zhihong Chen, Ph.D., Jia Huang, Ph.D. & Wei Zhang, Ph.D

CABA 2009 Medical Devices & Diagnostics Symposium was held at MIT faculty club on Dec. 5th, 2009. This event was hosted by Chinese-American BioMedical Association (CABA) and co-hosted by American Chinese Medical Association (ACMA). The main topics of this symposium included an overview of medical device & diagnostics industry in US as well as in China, market trend analysis and strategic planning, cutting-edge technology introduction and entrepreneurship in Medical Device & Diagnostics field both in US and China. The event also aimed to enhance interactions between physicians and biomedical academic/industrial professionals, to encourage innovation and entrepreneurship, and to understand current medical device & diagnostics industry in China.

The event attracted more than one hundred people including biotech & pharmaceutical company professionals, medical doctors, executives, professor, lawyers, medical device company CEO, and Chinese SFDA officer in medical device division of Hubei province.



Dr. Zhao-Kui Wan, President of CABA and Dr. Bill Lian, medical director of ACMA gave opening remarks at the beginning representing CABA and ACMA, respectively.

Dr. Zhihong Chen hosted first session in which an overview of medical device market was given by Dr. David O'Bryan, President of Boston Bimedical Consultants and a Market Analyst, Mr. Ji Shi. Ms. Regina Au, Principal of Biomarketing Insight gave a presentation on strategic planning. Dr. Jeffery Karp from Harvard Medical School introduced a new technology and advanced biomaterial that could be used for stem cell-based therapeutics. Finally, Dr. Xueji Zhang, Senior Vice President of World Precision Instrument, described a cutting-edge biosensor technology with many applications including that in space shuttle projects.

The second session was chaired by Dr. Jia Huang. In this session, Dr. Yanan Zhang talked about development of a glucose sensor for diabetes patients which will be manufactured in China. Dr. Tong Zhu, a cardiologist from Cardiovascular Center of Boston Medical Center presented an Implantable Cardioverter Defibrillator from a clinician's point of view. Shallwei Sun, President of Callisyn Biomedical shared her entrepreneur experience in China as a returnee from small start-up company business point of view. Dr. Xiaorong Sun, CEO, Wu-Han Landing Medical Hi-Tech Ltd introduced an Early Cancer Detection technology by Fully Automated Imaging Cytometry as well as her entrepreneur experience in China.



The audience was highly interested in the medical device topics, even after the presentation and question/answer time was delayed again and again, still there were too many questions from the audience. People were still talking, discussing in the hallway even after the meeting was closed. There is no doubt medical device is a very interesting topic and the symposium was a great success.

It is worthy emphasizing that Dr. Wei Zhang, the Chair of the organizing committee and Dr. Jia Huang, one of the co-chairs spent a lot of time and efforts putting together the program. Their hard work was paid off by the enthusiasm and active involvement of the audience, ie. CABA members.

CABA Event Announcement

The 2010 Chinese New Year Gala & Community Enrichment Forum

The 2010 Chinese New Year Gala & Community Enrichment Forum, co-organized by 12 associations, will be the very first time for nearly all major Chinese American professionals associations of Boston to come together to make bigger contributions to the local communities as a whole. The gala will feature Professional Workshops and Cultural Salons, Career Fair and Consultation, Musical Performances and Shows, Cocktail Social Hour and Valentine's Night Dinner, Dancing Balls and Karaoke Party. More importantly, it provides an unprecedented opportunity for networking with local Chinese American professionals, lawyers, doctors, scientists, engineers, entrepreneurs, artists, political leaders..... Please join us with your friends and family, and fill this special Chinese New Year Day and Valentine's night with happiness, excitement and unforgettable memories!



Gala Program:

§ Parallel Forums and Salons (2:00-5:00 pm)

- ¨ Medical/BioPharma/Healthcare Forum
- ¨ Information Technology Forum
- ¨ Entrepreneurship Forum
- ¨ Science, Technology & Business Exchange Forum
- ¨ Career Fair & Consultation
- ¨ Social/Cultural Salon

¨ Networking & Game

§ Cocktail Social Hour (5:00 -6:00 pm)

§ Keynote Speeches (6:00 - 7:00 pm)

§ Three-Course Valentine's Dinner (7:00 - 8:30 pm)

§ Performance & Cultural Shows (8:30 - 9:00 pm)

§ Dancing, Karaoke & Social Networking (9:00 - 10:00 pm)

Dress Code: Formal Attire

Tickets: \$50 (before Feb. 4); \$60 (afterwards). Tickets can be purchased on-line or at Kam Man Market of Quincy, Asian Culture Center of Woburn, and several Chinese schools (Acton, Newton, Cambridge, Century, etc).

Website: 2010ChineseGala.com

Sponsorship opportunities available! Please mark your calendar and stay tuned!

CABA Career Center**Biopharmaceutical and CRO Job Opportunities**

WuXi AppTec is a NYSE listed public company based in Shanghai, China. We offer global pharmaceutical / biopharmaceutical companies diverse outsourcing services in combinatorial, medicinal, synthetic chemistry and manufacturing of APIs and finished drug products for preclinical and clinical trials. Our rapid business expansion opens up the exciting positions as follows:

Shanghai Opportunities

- Vice President of Medicinal Chemistry
- Executive Director /Senior Director /Director of Medicinal Chemistry
- Project Team Leader of Medicinal Chemistry
- Principal Scientist/Senior Scientist of Medicinal Chemistry
- Senior Director /Director /Associate Director of Enzymology
- Executive Director/ Senior Director/ Director of Formulation Development
- Senior Director/ Director of Pre-formulation Development
- Executive Director/ Senior Director/ Director of Process R&D
- Senior Director/ Director of Analytical R&D
- Senior Director /Director /Associate Director of Receptor Pharmacology
- Research Fellow, In Vitro Biology
- Principal Scientist of Stem Cell Research
- Senior Scientist of Stem Cell Research
- Scientist of Stem Cell Research
- Executive Director/Senior Director/Director of DMPK

- Senior Director/Director of Pharmacology
- Senior Director/ Director of Analytical R&D/QC
- Computational Chemists

Suzhou Opportunities

- Study Director of Toxicology
- Veterinarian Ophthalmologist
- Attending Veterinarian
- Clinical Pathologist
- Pathologist
- Biologist III/Biocompatibility
- Biologist III/Trainer

Jinshan Opportunities

- Director of QC
- Tianjin Opportunities
- Executive /Senior Director/Director of Synthetic Chemistry
- Principle /Senior Scientist of Synthetic Chemistry

WuXi AppTec welcomes overseas talents join us. We offer you a highly competitive compensation and full benefits package along with an exciting world-class work environment in China. For more information, please visit our website: www.wuxiapptec.com.

For prompt consideration, please send your CV to: @wuxiapptec.com.



Sundia offers a competitive compensation and benefits package, and an exciting atmosphere conducive to career growth.

Associate Director/Director of Medicinal Chemistry

The responsibility of this person will be closely working with our clients to manage medicinal chemistry programs in our Shanghai facility. He or she needs to do project assessment such as compound design and synthetic route evaluation, data managing and mining, and resource allocation. Another aspect of this person's responsibility is to effectively communicate with our clients on a routinely basis.

A successful candidate should have a Ph.D. degree in synthetic organic chemistry or medicinal chemistry, and over 6 years of drug discovery experience in US or Europe pharmaceutical/biotech companies with a strong scientific track record. Understanding the drug discovery process and operation within an aggressive timeline is required. In addition, the candidate should be able to solve problems associated with medicinal chemistry.

Interested individuals shall send a cover letter indicating the position applied for and the skills matched, along with a resume including references and publications. E-mail to hr@sundia.com with your resume or inquiries about openings. Or contact us by the mailing address:

Human Resources
Sundia MediTech Company Ltd.,
Building 8, 388 Jialilue Road,
Zhangjiang High-Tech Park,
Shanghai, China 201203 For more
information, please visit our
website: [://www.sundia.com/](http://www.sundia.com/)



ARIAD Pharmaceuticals is a Cambridge, Massachusetts-based biotechnology company focused on cancer. We look for a variety of skills and achievements in our employees, supported by diverse work experience and excellence in education. Success in our product development and scientific programs has created openings in many areas of the company.

Clinical Affairs

- Clinical Research Specialist - Oncology

Drug Safety

- Drug Safety Specialist

Manufacturing

- Director, Supply Chain and Distribution (Clinical & Commercial)
- Manager, Clinical Supply Chain
- Research Scientist, Chemical and Process Development
- Senior Staff / Principal Scientist, Analytical Development

Regulatory & Quality

- Quality Assurance Auditor (GCP)

Regulatory Affairs

- Sr. Regulatory Affairs Associate

Research Technology

- Principal Scientist / Associate Director, DMPK, Ph.D.
- Staff Scientist, Enzymology, Ph.D.

For more information, please visit our website: ariad.com.



Concert Pharmaceuticals is dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Our culture is fast-paced, cutting edge, and collegial. We expect and reward high performance and a sense of urgency, an

interdisciplinary mindset, learning and teaching, self-motivation, leadership, and focus on contribution to corporate goals. Concert offers tremendous growth opportunity for individuals with the right experience, and we are actively recruiting motivated professionals who have the ability to work in a fast-paced startup environment. If you would like to be considered for a job on the Concert team, send your resume in the body text of an e-mail (no attachments please) to: @concertpharma.com.

- Sr. Director/Director, In-Vivo Pharmacology

Qualifications: Doctorate Degree in Pharmacology (or equivalent degree) and a minimum of 7 years experience in pharmaceutical product development, with a proven record of technical publications across several disease model areas. Must possess strong Project/Program management experience with regard to preclinical development plans and design. Must have a strong technical understanding of biochemical pathways as well as the pathophysiology of disease states. Strategic leadership experience is highly desired in addition to extensive experience in the management of external collaborations and CROs. Must be highly motivated, flexible and a strong team player able to excel in a dynamic matrix environment. Strong communication, interpersonal, and organizational skills are essential.

- Director, Clinical Pharmacology/Toxicology

Qualifications: Ph.D. in pharmacology or pharmacokinetics or a PharmD with a clinical pharmacology/toxicology research fellowship or equivalent. Minimum of 8 years relevant experience gained through direct industry experience in Clinical Pharmacology/Toxicology is required.

Experience in being a Study Director contributing to the pharmacokinetic and pharmacodynamic aspects of clinical protocol design, writing, data interpretation, review and reporting of results for multiple studies of different types for multiple projects. Knowledge in state-of-the-art in vitro and in vivo toxicological techniques for developing a non-clinical safety/toxicology package. Must have experience developing at least one or more clinical pharmacology plans. Demonstrated experience in preparing regulatory submissions, including toxicology reports, full NDAs or significant sNDAs, as well as multiple INDs. Experience responding to regulatory questions related to pharmacokinetics and pharmacodynamics and toxicology. Application and knowledge of current practices and issues in the following areas for multiple projects clinical pharmacology, bioanalytical, biopharmaceutics, regulatory, metabolism and non-clinical ADME and toxicology.

- Scientist, Chemistry

Qualifications: * Ph.D. in Synthetic Organic or Medicinal Chemistry * 0-2 years of relevant experience * Proven track record of innovation and productivity in small molecule pharmaceutical research. * Ability to work independently and to interact with a multidisciplinary team of internal and external scientists. * Experience with modern structure-based drug design and multi-parallel synthesis is a plus. * Excellent oral / written communication and presentation skills * Flexibility to work in a dynamic environment

Contact Us: To learn more about this position or to apply, please contact us at @concertpharma.com.

CABA Membership Update**CABA 2009-2010 Board of Directors and Executive Committee Members****President**

Zhao-Kui Wan, Ph. D. (Pfizer, USA)

Vice President

Chaoyang Dai, Ph. D. (Merck, USA)

Zhiyong Yang, Ph. D. (Pfizer, USA)

Executive Committee Members

Qinglin Che, Ph. D. (Synta Pharmaceuticals, USA)

Zhihong Chen, Ph. D. (Eisai Research Institute, USA)

Kevin Fang, Ph. D. (Sepracor Inc, USA)

Jinbo Lee, Ph.D. (Sage Partner International, USA)

Shiwen Lin, Ph. D. (Antigenics, Inc, USA)

Fushuang Liu (Wuxi Howfond Biopharma, China)

Sue Ma, M. D. (Novartis, USA)

Haihong Ni, Ph. D. (Chemizon, China)

Lixin Shen, Ph. D. (Wuxi Howfond Biopharma, China)

Shallwei Sun (Callisyn Inc, China)

Ze Tian, Ph. D. (Children's Hospital Boston/Harvard Medical School, USA)

Yihan Wang, Ph. D. (ARIAD

Pharmaceuticals, USA)

Yongzhong Wang, Ph. D. (Genzyme, USA)

Zhiqiang Wang, Ph. D. (Pfizer, USA)

Erxi Wu, Ph. D. (North Dakota State University, USA)

Roger Xie, Ph. D. (China PharmaHub Corp, USA)

Herong Yang, Ph. D. (Open Channel Solutions, USA)

Yongwen(Tony) Yuan (Novartis, USA)

Philip Zhang, Ph. D. (Milstein Zhang & Wu LLC, USA)

Weiyi(Wendy) Zhang, Ph. D. (Sundia MediTech, China)

Liping Zhou, Ph. D. (Novartis, USA)

Zhendong Zhu (Avila Therapeutics, USA)

Founding President

Jun Han, Ph. D. (Teva Pharmaceuticals, USA)

Immediate Past-President

Junjun Wu, Ph. D. (Pfizer, USA)

CABA Legal Counsel

Fred Gilman

Attorney at Law, Lynch, DeSimone & Nylen, LLP, Boston, MA

CABA Advisors

Tomi Sawyer, Ph. D., Chief Scientific Officer and Senior Vice-President, Aileron

Therapeutics, Cambridge, MA

Yibin Xiang, Ph. D., Senior Director/Medicinal Chemistry, Genzyme Corporation, Cambridge, MA

Steve Tam, Ph. D., Senior Director/Chemistry, Wyeth Research, Cambridge, MA

Gangfeng Xu, Ph. D., VP/Head of Asia & Pacific Business Development, Wyeth Research, NY

Jianling Wang, Ph. D., Section Manager, Novartis Institute of BioMedical Research, Cambridge, MA

Howard Yuwen, Ph. D., Sr. Director, Shire Pharmaceuticals, Cambridge, MA

Wei Zhang, Ph. D., Director, Market Research, Altus Pharmaceuticals Inc., Cambridge, MA

Chen Li, Ph. D., Head of Research and Chief Scientific Officer, Roche R&D Center(China) Ltd.

Steve Yang, Ph. D., Vice President and Head of Pfizer Asia R&D(Shanghai), Shanghai, China

Tim Clackson, Ph. D., Sr. VP and Chief Scientific Officer, Ariad Pharmaceuticals Inc., Cambridge, MA

Youssef Bennani, Ph. D. Vice President/Discovery Chemistry, Vertex Pharmaceuticals Inc., Cambridge, MA

Dawei Ma , Ph. D. Professor, Shanghai Institute of Organic Chemistry, Shanghai, China

Roger Tung, Ph. D., CEO and President, Concert Pharmaceuticals, Lexington, MA

Steve Projan, Ph. D., Vice President, Global Head of Infectious Diseases, Novartis Institute of BioMedical Research, Cambridge, MA

John Piwinski, Ph. D., Group VP and Site Head, Schering-Plough Research Institute, Cambridge, MA

Tarek Mansour, Ph. D., VP and Head of Chemical Sciences, Wyeth Research Institute, Wyeth Pharmaceuticals

Liming Shao, Ph. D. Senior Director/Medicinal Chemistry, Sepracor Inc., Marlborough, MA

Pierre Frederic Dodion, Senior Vice President and Chief Medical Officer, ARIAD Pharmaceuticals, Cambridge, MA

Sponsor Spotlights

CABA 2009 Sponsors Highlight



Upcoming Events

Reach thousands of professionals, executives and scientific researchers in biomedical industries throughout the world!

Advertise in CABA CONNECT
Contact our advertisement editor at cabacconnect@gmail.com

CABA members, send your comments, suggestions and thoughts to us; Contribute to "Member Spotlights" column by sending us a brief summary of your recent achievements on academics or/and careers.

Volunteer coordinator needed for news reporting, editing and photography. Contact us at cabacconnect@gmail.com if you are interested.

New England Chinese Professionals Lunar New Year Gala and the Community Enrichment Forum

Co-organized by CABA, ACMA, CAIPLA, OCEAN, NECINA and others
Saturday, Feb 14th, 2010
Time: 2:00 PM - 10:00 PM
Location: Marriot Newton Hotel, Massachusetts
Website: www.2010ChineseGala.com

2010 CABA Annual Conference

Organized by CABA
Saturday, April 10th, 2010
Time: 9:00 AM – 9:30 PM
Location: MIT Faculty Club
Website: www.cabaweb.org

China 2010 Pharmaceutical R&D Summit

Organized by IBC Life Sciences
April 05 - 08, 2010
Location: Grand Hyatt Hotel, Shanghai, China
Website: <http://www.ibclifesciences.com/china/overview.xml>

Drug R&D in China – Status, Opportunity, International Collaboration and Challenges 中国新药研究的现状和远景，国际合作的机遇及挑战

Organized by NESACS, co-organized by CABA and SAPA-NE
Saturday, May 22nd, 2010
Location: Holiday Inn, 15 Middlesex Canal Park Road, Woburn, MA
Time: 8:30 AM – 9:00 PM



Chinese-American Biomedical Association
P. O. Box 600241
Newtonville, MA 02460 USA
www.cabaweb.org

Non-profit Org.
US postage paid
Newton, MA 02460